当前位置: X-MOL 学术Ann. Hematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
Annals of Hematology ( IF 3.5 ) Pub Date : 2020-01-23 , DOI: 10.1007/s00277-020-03917-7
Omar Alkharabsheh 1 , Mrinal M Patnaik 2 , Naseema Gangat 2 , Kebede H Begna 2 , Hassan B Alkhateeb 2 , Mithun Vinod Shah 2 , William J Hogan 2 , Rong He 3 , Patricia Greipp 3 , Phuong L Nguyen 3 , Mark R Litzow 2 , Aref Al-Kali 2
Affiliation  

Clinical trials and treatment guidelines for myelodysplastic syndrome depend on several prognostic scoring systems to stratify patients by risk. These include different variables: the degree of cytopenia, percentage of bone marrow blasts, and cytogenetics. Little is known about the impact of bone marrow blasts in patients with adverse cytogenetics. In this retrospective study, we analyzed 536 patients with high-grade myelodysplastic syndrome to examine the differences in survival for patients with different percentages of bone marrow blasts. The median overall survival in patients with ≥ 5% marrow blasts was not statistically different from that for patients with < 5% marrow blasts; however, the former group had a higher risk of progression to acute myeloid leukemia (p < 0.001). Therefore, cytogenetics is the most important factor in our prognostic tools to determine survival outcomes for patients with myelodysplastic syndrome, and patients with high-risk disease have poor prognosis irrespective of their marrow blasts percentage.

中文翻译:

使用修订后的国际预后评分系统评估了骨髓母细胞百分率对高等级骨髓增生异常综合症的影响。

骨髓增生异常综合症的临床试验和治疗指南取决于几种预后评分系统,以根据风险对患者进行分层。这些变量包括不同的变量:血细胞减少症的程度,骨髓母细胞的百分比和细胞遗传学。对于不良细胞遗传学患者骨髓母细胞的影响知之甚少。在这项回顾性研究中,我们分析了536名严重骨髓增生异常综合症患者,以检查不同百分比的骨髓母细胞患者的生存率差异。骨髓母细胞≥5%的患者的中位总生存率与骨髓母细胞<5%的患者的中位总生存率无统计学差异。然而,前一组患急性髓性白血病的风险更高(p <0.001)。因此,
更新日期:2020-03-06
down
wechat
bug